top of page

Inositec secures $1.42m financing to advance new class of inositol hexaphosphate-based drug candidat

Inositec, which is engaged in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), has closed a CHF1.4m ($1.42m) seed financing.

Investors participating in the round included VI Partners via the Venture Incubator fund and Zürcher Kantonalbank. The proceeds will be used to progress a drug candidate from Inositec’s proprietary Inositune platform through preclinical proof-of-concept.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page